GSK Can't Quash $106 Mil. Verdict in Generic Paxil Dispute

, New Jersey Law Journal

   | 0 Comments

A Trenton, N.J., federal judge has denied GlaxoSmithKline's bid to toss out a $106 million verdict against it for breaching a contract granting Mylan Pharmaceuticals exclusive rights to make a generic version of the antidepressant Paxil CR.

What's being said

Comments are not moderated. To report offensive comments, click here.

Preparing comment abuse report for Article# 1202663613488

Thank you!

This article's comments will be reviewed.